Search Within

Alexander Meyer Lesokhin

Formats
  1. Meeting Abstract (252)
  2. Journal Article (103)
  3. Research Letter (11)
  4. Review (7)
  5. Correspondence (4)
  6. Book Section (2)
  7. Editorial (2)
Groups
  1. Center for Hematologic Malignancies (381)
  2. Department of Medicine (381)
  3. Hematologic Malignancies Research (381)
  4. Hematologic Malignancies, Division of (381)
  5. Myeloma (381)
  6. Survivorship Research (225)

More Groups

People
  1. Hani Hassoun (202)
  2. Heather Landau (187)
  3. Sergio Giralt (185)
  4. David Chung (175)
  5. Neha Korde (174)
  6. Sham Mailankody (170)

More People

Years
  1. 2025 (12)
  2. 2024 (52)
  3. 2023 (77)
  4. 2022 (51)
  5. 2021 (31)
  6. 2020 (18)

More Years

Publications
  1. Blood (140)
  2. Clinical Lymphoma, Myeloma and Leukemia (57)
  3. Journal of Clinical Oncology (41)
  4. Biology of Blood and Marrow Transplantation (13)
  5. Leukemia and Lymphoma (13)
  6. Blood Advances (12)

More Publications

Publishers
  1. American Society of Hematology (152)
  2. Elsevier Inc. (79)
  3. American Society of Clinical Oncology (41)
  4. Nature Publishing Group (26)
  5. American Association for Cancer Research (14)
  6. Taylor & Francis Group (13)

More Publishers

Results (381)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Rajeeve, S.; Jurgens, E.; Nishimura, N.; Farzana, T.; Firestone, R.; Miller, K.; Lesokhin, A.; Shah, G.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Real-world safety and early efficacy of talquetamab in patients with heavily-pretreated relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Tan, C.; Shekarkhand, T.; Firestone, R.; Jurgens, E.; Miller, K.; Lesokhin, A.; Shah, G.; Korde, N.; Rajeeve, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Maintenance therapy cessation for multiple myeloma patients with three-year sustained mrd negative remissions
    Meeting Abstract

    Korde, N.; Hassoun, H.; Landau, H.; Hamid, S.; Derkach, A.; Hultcrantz, M.; Mailankody, S.; Tan, C.; Shah, U.; Maclachlan, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Para-medullary (PMD) and extra-medullary (EMD) myeloma demonstrate increased copy number aberration, mutational burden, structural variants and genomic complexity compared to marrow-based myeloma
    Meeting Abstract

    Maclachlan, K.; Garcés, J. J.; Shekarkhand, T.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Tan, C.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Clinical response and pathway-specific correlates following TIGIT–LAG3 blockade in myeloma: The MyCheckpoint randomized clinical trial
    Journal Article

    Richard, S.; Lesokhin, A. M.; Paul, B.; Kaufman, J. L.; Pianko, M.; Biran, N.; Vij, R.; Doxie, D. B.; Azeem, M. I.; Martillo, M.; more...
    Nature Cancer (2024)

    Fulltext@MSK | Save
  • Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma
    Research Letter

    Hultcrantz, M.; Hassoun, H.; Korde, N.; MacLachlan, K.; Mailankody, S.; Patel, D.; Shah, U. A.; Tan, C. R.; Chung, D. J.; Lahoud, O. B.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Evaluation of cytokine release syndrome (CRS) in patients with relapsed or refractory multiple myeloma (RRMM) receiving step-up priming doses and longer dosing intervals of elranatamab: MagnetisMM-9
    Meeting Abstract

    Sborov, D. W.; Pawlyn, C.; Ishida, T.; Huang, J. S. Y.; Benjamin, R.; Iida, S.; Popat, R.; Kuroda, J.; Pianko, M. J.; Ramakrishnan, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma: CARTITUDE-2 cohort A expansion subgroup
    Meeting Abstract

    Cohen, A. D.; Voorhees, P. M.; Martin, T. G.; Lesokhin, A. M.; Hillengass, J.; Kaufman, J. L.; Schecter, J. M.; De Braganca, K. C.; Varsos, H.; Corsale, C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM)
    Meeting Abstract

    Lesokhin, A. M.; Raza, M. S.; Acosta, J.; Muller, P.; O'Connell, A.; Yver, A.; Lou, C.; Finn, G.; Service, M.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Real-world schedule de-escalation of teclistamab in patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Tan, C. R. C.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Shah, G. L.; Scordo, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save